Legal Blog

Read & Share: How Close Is The World To A Coronavirus Vaccine?

The rush to develop a COVID-19 vaccine is heating up with the CDC telling U.S. states to be ready to destribute (sic) one by early November while Russia is already aiming to bring its Sputnik V innoculation (sic) to the market this month. Scientists have warned that candidates that have not completed trials may make the pandemic worse, however. Great hopes have been pinned on a coronavirus vaccine candidate being developed by the University of Oxford that successfully triggered a strong immune response in trials involving 1,077 people last month. Yet, Phase III trials were halted on Wednesday after a participant came down with an unexplained illness. Pharmaceutical company AstraZeneca, which partners with the University of Oxford on the development of the vaccine, called the pause a “routine” procedure.

So far, the vaccine did not show any dangerous side effects but, 70 percent of participants in the trial experienced a headache or fever, which scientists said could be managed by paracetamol.

Scientific journal The Lancet had published hugely promising results of Phase I/II trials in July for the University of Oxford vaccine, and they have raised hopes that a safe, effective and accessible vaccine will be attainable to help end the pandemic. The trial provoked a T cell response within 14 days of vaccination and an antibody response within 28 days.

Quoted from Statista


Do you want to vet a business opportunity? Is there an anticipated commercial dispute? Is a second legal opinion warranted? Grab 15 minutes with me, and I will work with you to understand your situation and provide my thoughts based upon successfully representing business owners for almost 25 years. You will receive a confirmation with a Teams Meeting invitation after you pick a time for our discussion. You can also reach out to me at

Have an interesting, fast fact for a business audience? Please send and share it with our 1,600+ subscribers. Click here to subscribe to Read & Share and receive fast facts delivered weekly.



Mike Mercurio | | 301-575-0332

Michael N. Mercurio is a leading attorney in the field of mergers and acquisitions (M&A). He serves as outside general counsel in buy-side and sell-side M&A, as well as in all business law and real estate law matters. As a strategic partner to firm clients, Mr. Mercurio regularly counsels entrepreneurial individuals and assorted entities on the many challenges, issues, and opportunities companies face throughout the business lifecycle—from start-up to eventual exit.







Offit Kurman is one of the fastest-growing full-service law firms in the United States. With 14 offices in seven states, and the District of Columbia, and growing by 50% in two years through expansions in New York City and Charlotte, North Carolina, Offit Kurman is well-positioned to meet the legal needs of dynamic businesses and the individuals who own and operate them. For over 30 years, we’ve represented privately held companies and families of wealth throughout their business life cycles.

Whatever and wherever your industry, Offit Kurman is the better way to protect your business, preserve your family’s wealth, and resolve your most challenging legal conflicts. At Offit Kurman, we distinguish ourselves by the quality and breadth of our legal services—as well as our unique operational structure, which encourages a culture of collaboration and entrepreneurialism. The same approach that makes our firm attractive to legal practitioners also gives clients access to experienced counsel in every area of the law.

Find out why Offit Kurman is The Better Way to protect your business, your assets and your family by connecting via our Blog, Facebook, Twitter, Instagram, YouTube, and LinkedIn pages. You can also sign up to receive LawMatters, Offit Kurman’s monthly newsletter covering a diverse selection of legal and corporate thought leadership content.